What oral antibiotic regimen should be started for a patient with an infected abrasion, taking into account possible MRSA risk factors and drug allergies?

Oral Antibiotic Management of Infected Abrasions

For an infected abrasion, initiate empiric oral antibiotic therapy targeting both methicillin-susceptible Staphylococcus aureus (MSSA) and β-hemolytic streptococci, with MRSA coverage added when risk factors are present. 1

Risk Stratification for MRSA

Before selecting antibiotics, assess for MRSA risk factors:

• High-risk indicators include: prior MRSA infection, recent hospitalization (within 90 days), recent antibiotic use (within 4–6 weeks), nasal MRSA colonization, injection drug use, close contact with someone with MRSA, or residence in a long-term care facility 2, 1
• If ≥1 risk factor is present, empiric MRSA coverage is warranted 1
• If no risk factors exist, target MSSA and streptococci only 1

First-Line Regimens by Risk Category

For Patients WITHOUT MRSA Risk Factors

• Cephalexin 500 mg orally four times daily for 5–7 days provides excellent coverage of MSSA and streptococci 2, 3
• Alternative: Dicloxacillin 500 mg orally four times daily for 5–7 days offers comparable efficacy but requires more frequent dosing 4
• Amoxicillin-clavulanate 875/125 mg orally twice daily for 5–7 days is appropriate when broader gram-negative or anaerobic coverage is needed (e.g., contaminated wounds, animal/human bites) 3, 4

For Patients WITH MRSA Risk Factors

• Trimethoprim-sulfamethoxazole (TMP-SMX) double-strength (160/800 mg) orally twice daily for 5–10 days is the preferred first-line agent, providing 90–95% coverage of community-associated MRSA (CA-MRSA) 1, 5
  • Critical limitation: TMP-SMX lacks reliable activity against β-hemolytic streptococci; therefore, add amoxicillin 500 mg orally three times daily or cephalexin 500 mg orally four times daily to ensure streptococcal coverage 1
• Doxycycline 100 mg orally twice daily for 5–10 days is an acceptable alternative with good CA-MRSA activity (85–90% susceptibility) and adequate streptococcal coverage 1, 5
  • Contraindicated in children <8 years and pregnant women 1
• Clindamycin 300–450 mg orally three times daily for 5–10 days covers both MRSA and streptococci but carries a 10–20% inducible resistance rate in CA-MRSA; reserve for patients intolerant of TMP-SMX and doxycycline 1, 5

Penicillin Allergy Considerations

• Non-severe (Type IV) penicillin allergy: Cephalosporins (cephalexin, cefdinir) are safe; cross-reactivity is <1% 2, 4
• Severe (Type I/anaphylactic) penicillin allergy: Avoid all β-lactams; use clindamycin, doxycycline, or TMP-SMX plus azithromycin (for streptococcal coverage) 1, 5

Treatment Duration and Monitoring

• Standard course: 5–7 days for uncomplicated superficial infections 2, 1
• Extend to 10 days if systemic signs are present (fever, lymphangitis, regional lymphadenopathy) or if the infection involves deeper structures 1, 3
• Reassess at 48–72 hours: If no clinical improvement (reduced erythema, warmth, tenderness), consider treatment failure and switch to an alternative agent with MRSA coverage 1, 5

Adjunctive Measures

• Incision and drainage is the primary intervention for purulent collections (abscesses); antibiotics are adjunctive 1
• Wound care: Keep the area clean, apply topical antiseptics (e.g., mupirocin 2% ointment twice daily for localized impetigo), and cover with sterile dressings 1, 3
• Elevation and immobilization of the affected limb reduce swelling and promote healing 3

Red Flags Requiring Urgent Evaluation or Parenteral Therapy

• Rapidly spreading erythema (>5 cm from wound edge in 24 hours) suggests aggressive infection 2
• Systemic toxicity: Fever >38.5°C, tachycardia >110 bpm, hypotension, or altered mental status 2
• Immunocompromised state: Diabetes, HIV, chronic corticosteroid use, or neutropenia 2, 1
• Failure of oral therapy after 48–72 hours mandates parenteral antibiotics (vancomycin 15–20 mg/kg IV every 8–12 hours or daptomycin 4 mg/kg IV daily) 1, 5, 6

Common Pitfalls to Avoid

• Do not use TMP-SMX as monotherapy for skin infections; always add β-lactam coverage for streptococci 1
• Avoid fluoroquinolones (e.g., levofloxacin, ciprofloxacin) as first-line agents; they have poor MRSA activity and promote resistance 1, 5
• Do not prescribe macrolides (azithromycin, erythromycin) empirically; resistance rates in S. aureus exceed 30–40% 1, 4
• Ensure adequate treatment duration (minimum 5 days); premature discontinuation increases relapse risk 1, 3